Ketone Body Therapy for Neurodegenerative Diseases
Overview
flowchart TD
Ketone_Body_Therapy_for_Neurod["Ketone Body Therapy for Neurodegenerative Diseas"]
Ketone_Body_Therapy_for_Neurod["Neurodegenerative"]
Ketone_Body_Therapy_for_Neurod -->|"related to"| Ketone_Body_Therapy_for_Neurod
style Ketone_Body_Therapy_for_Neurod fill:#81c784,stroke:#333,color:#000
Ketone_Body_Therapy_for_Neurod["table"]
Ketone_Body_Therapy_for_Neurod -->|"related to"| Ketone_Body_Therapy_for_Neurod
style Ketone_Body_Therapy_for_Neurod fill:#81c784,stroke:#333,color:#000
Ketone_Body_Therapy_for_Neurod["class"]
Ketone_Body_Therapy_for_Neurod -->|"related to"| Ketone_Body_Therapy_for_Neurod
style Ketone_Body_Therapy_for_Neurod fill:#81c784,stroke:#333,color:#000
style Ketone_Body_Therapy_for_Neurod fill:#4fc3f7,stroke:#333,color:#000
...
Ketone Body Therapy for Neurodegenerative Diseases
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic"> <tr> <th class="infobox-header" colspan="2">Ketone Body Therapy for Neurodegenerative Diseases</th> </tr> <tr> <td class="label">Trial</td> <td>Intervention</td> </tr> <tr> <td class="label">BHB drink study</td> <td>30g BHB daily</td> </tr> <tr> <td class="label">Ketogenic diet</td> <td>Classic KD</td> </tr> <tr> <td class="label">ketone ester</td> <td>KE vs Placebo</td> </tr> <tr> <td class="label">Formulation</td> <td>Dose</td> </tr> <tr> <td class="label">BHB salts</td> <td>10-30g</td> </tr> <tr> <td class="label">Ketone ester</td> <td>25-50g</td> </tr> <tr> <td class="label">Medium-chain triglycerides</td> <td>20-30g</td> </tr> <tr> <td class="label">Trial ID</td> <td>Intervention</td> </tr> <tr> <td class="label">NCT04636524</td> <td>BHB drink</td> </tr> <tr> <td class="label">NCT05328435</td> <td>Ketone ester</td> </tr> <tr> <td class="label">NCT04531085</td> <td>KD</td> </tr> </table>
Ketone body therapy represents an emerging metabolic approach to treating neurodegenerative diseases by providing alternative energy substrate to the aging brain. This therapy leverages the neuroprotective effects of ketone bodies, particularly beta-hydroxybutyrate (BHB), to support mitochondrial function and reduce neurodegeneration across multiple disease states["@puchowicz2020"].
Mechanism of Action
When administered exogenously, ketone bodies provide an alternative fuel source to glucose:
Beta-hydroxybutyrate (BHB) - Primary circulating ketone body
Acetoacetate (AcAc) - Converted to BHB
Acetone - Minor ketone body (expired)The brain preferentially oxidizes ketone bodies over glucose, particularly in regions affected by neurodegeneration[@veech2017].
Mitochondrial Function Ketone bodies enhance mitochondrial health through:
Improved ATP production : Ketone oxidation yields more ATP per oxygen molecule
Reduced [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) : Ketone metabolism produces fewer ROS
Enhanced mitochondrial biogenesis : BHB activates PGC-1α
Improved mitochondrial dynamics : Regulates fusion/fission balance
Molecular Signaling Beyond energy production, BHB functions as a signaling molecule:
[HDAC](/entities/hdac-enzymes) inhibition : BHB inhibits class I histone deacetylases
[NLRP3 inflammasome](/entities/nlrp3-inflammasome) suppression : Reduces neuroinflammation
[Autophagy](/entities/autophagy) induction : Promotes clearance of damaged proteins
BDNF enhancement : Supports neuronal survival
Alzheimer's Disease
Evidence Strength: Strong Ketone body therapy has the strongest evidence base in Alzheimer's disease.
Clinical Trials:
Proposed Benefits in AD:
Improved cerebral glucose metabolism
Reduced amyloid burden (preclinical)
Neuroinflammation reduction
Mitochondrial function preservation
Parkinson's Disease
Evidence Strength: Emerging Ketone therapy in PD shows promise based on:
Preclinical Evidence:
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model: BHB protected dopaminergic [neurons](/entities/neurons)[@tieu2003]
Improved motor function in PD models
Reduced [alpha-synuclein](/proteins/alpha-synuclein) aggregation
Clinical Evidence:
Pilot study: Ketogenic diet improved motor scores (UPDRS)
Open-label trials: Benefits in non-motor symptoms
Ongoing Phase 2 trials
Amyotrophic Lateral Sclerosis (ALS)
Evidence Strength: Preclinical Preclinical Evidence:
SOD1 mouse model: Ketogenic diet extended survival
Reduced motor neuron loss
Improved mitochondrial function
Clinical Status:
Small pilot studies completed
No large-scale trials yet
Rationale: Energy metabolism is impaired in ALS
Tauopathies (CBS, PSP, FTD)
Evidence Strength: Limited but Plausible Biological Plausibility:
[Tau](/proteins/tau) pathology associated with metabolic dysfunction
Ketone bodies may improve tau phosphorylation
Neuroinflammation common to all tauopathies
Current Evidence:
No human trials specifically in CBS/PSP
Case reports in FTD showing cognitive benefits
Strong preclinical rationale
Huntington's Disease
Evidence Strength: Limited Evidence:
Preclinical: Improved motor function in R6/2 mice
Human: Ketogenic diet pilot showed safety
Rationale: Energy deficit is prominent in HD
Dosing Protocols
Ketogenic Diet
Classic: 70-80% fat, 15-20% protein, 5-10% carbs
Modified Atkins: 65% fat, 30% protein, 5% carbs
Time-restricted: Daily fasting window
Clinical Monitoring
Blood ketone levels: Target 1-5 mM
Adverse effects: GI symptoms, constipation
Contraindications: Pancreatitis, liver disease
Clinical Trials
Active/Completed Trials
Biological Plausibility Gaps
Research Needs
Optimal dosing : What is the therapeutic window?
Biomarkers : How to predict responders?
Long-term effects : Safety beyond 2 years
Combination therapy : Synergy with other treatments
Genetic factors : [APOE](/proteins/apoe) genotype effects
Unknowns
Mechanism of ketone-induced neuroprotection
Role of gut [microbiome](/entities/microbiome) in response
Optimal timing for intervention
Effects on disease progression vs. symptoms
Side Effects and Safety
Common Adverse Events
Gastrointestinal distress
Constipation
Bad breath (acetone)
Initial fatigue
Contraindications
Pancreatitis
Severe liver disease
Type 1 diabetes (risk of ketoacidosis)
Eating disorders
Related Pages
[Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-ad)
[Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinsons)
[Metabolic Dysfunction in Neurodegeneration](/mechanisms/metabolic-dysfunction-neurodegeneration)
[Ketogenic Diet Research](/therapeutics/ketogenic-diet-therapeutics)
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Puchowicz MA, et al, Ketogenic diet as a metabolic therapy for neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32654321/)
Veech RL, The therapeutic implications of ketone body metabolism (2017)
Newport MT, et al, A new way to generate ketone bodies for treating neurological disorders (2015)
Tieu K, et al, Beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease (2003)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[The Glial Ketone Metabolic Shunt Hypothesis](/hypothesis/h-4b517512) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: HMGCS2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
Related Analyses:
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Show full description